Cantor Fitzgerald Issues Negative Forecast for ZVRA Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings estimate for Zevra Therapeutics from $1.58 to $0.99 per share while maintaining an "Overweight" rating with a $29.00 target price.
• Zevra Therapeutics reported a quarterly EPS of (0.06), significantly missing the consensus estimate of $1.43 by $1.49, despite revenues exceeding expectations at $25.88 million.
• Institutional investors are actively increasing their stakes in Zevra Therapeutics, with a notable 462.4% increase in holdings by Adage Capital Partners GP L.L.C. in the fourth quarter.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn $0.99 per share for the year, down from their previous estimate of $1.58. Cantor Fitzgerald currently has a "Overweight" rating and a $29.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Cantor Fitzgerald also issued estimates for Zevra Therapeutics' FY2026 earnings at $0.55 EPS.

Several other research firms also recently weighed in on ZVRA. JMP Securities cut their price target on Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen downgraded Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 20th. HC Wainwright assumed coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price target on the stock. Finally, Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.71.

Zevra Therapeutics Stock Down 2.4%

Shares of Zevra Therapeutics stock traded down $0.23 during midday trading on Friday, hitting $9.20. The company had a trading volume of 1,225,719 shares, compared to its average volume of 1,477,849. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The stock has a market capitalization of $516.40 million, a P/E ratio of -43.81 and a beta of 1.87. The company has a 50 day moving average of $10.56 and a 200 day moving average of $8.77. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16.

Institutional Trading of Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in ZVRA. Ameritas Investment Partners Inc. boosted its stake in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company's stock valued at $49,000 after purchasing an additional 1,280 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth $53,000. GAMMA Investing LLC boosted its stake in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after buying an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock worth $88,000 after buying an additional 8,552 shares during the last quarter. Finally, Creative Planning purchased a new position in shares of Zevra Therapeutics in the 2nd quarter worth $92,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.